PEK fusion protein vaccine

Drug Profile

PEK fusion protein vaccine

Alternative Names: PE-E7-K3

Latest Information Update: 25 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Healthbanks Biotech Co
  • Class Cancer vaccines; Protein-vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cervical intraepithelial neoplasia

Most Recent Events

  • 14 Jun 2013 HealthBanks Biotech completes enrolment in its phase I trial for Cervical intraepithelial neoplasia in USA (NCT01880411)
  • 13 Jun 2013 Phase-I for Cervical intraepithelial neoplasia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top